Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions: Colocalization implicates TGF- β in fibrofatty lesion development

Circulation

Volumn 99, Issue 22, 1999, Pages 2883-2891

  Bobik, Alex ^c   Agrotis, Alex ^d   Kanellakis, Peter ^d   Dilley, Rodney ^d   Krushinsky, Anatoly ^a,b   Smirnov, Vladimir ^a,b   Tararak, Eduard ^a,b   Condron, Melanie ^d   Kostolias, Gina ^d  

^a ALFRED HOSPITAL   (Australia)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d NONE

Author keywords

Atherosclerosis; Cells; Immunohistochemistry; Lesion; Receptors

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ABDOMINAL AORTA; ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTERY INTIMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; TISSUE DISTRIBUTION;

EID: 0033536016     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2883     Document Type: Article

References (30)

1. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
2. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
4. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
5. Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGFβ. Cardiovasc Res. 1995;29:848-855.
6. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL Jr. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest. 1997;100:2182-2188.
7. Chen J-K. Hoshi H, McKeehan WL. Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1987;84: 5287-5291.
8. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98:519-527.
9. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogl S, Dargel R, Poll G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J. 1997;11:851-857.
10. Falcone DJ, McCaffrey TA, Mathew J, McAdam K, Borth W. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-β1 via increased expression of urokinase and the urokinase receptor. J Cell Physiol. 1995;164:334-343.
11. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. Transforming growth factor-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer. 1998;75:721-730.
12. Libby P, Clinton SK. The role of macrophages in atherogenesis. Curr Opin Lipidol. 1993;4:355-363.
13. Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-β1 in mice: stimulation by cyclosporine. Transplantation. 1997;63:1037-1039.
14. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
15. Ward MR, Agrotis A, Kanellakis P, Dilley R, Jennings G, Bobik A. Inhibition of protein tyrosine kinase attenuates increases in expression of transforming growth factor-β isoforms and their receptors following arterial injury. Arterioscler Thromb Vasc Biol. 1997;17:2461-2470.
16. Krushinsky AV, Nestaiko GV. Morphology of smooth muscle cells from normal and atherosclerotic human aorta. Soc Med Rev A Cardiol. 1987; 1:35-73.
17. - -dependent mechanism. Circ Res. 1990;67:814-825.
18. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwanz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994; 89:2462-2478.
19. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwanz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15:1512-1531.
20. Chiu DS, Oram JF, LeBoeuf RC, Alpers CE, O'Brien KD. High-density lipoprotein-binding protein (HBP)/vigilin is expressed in human atherosclerotic lesions and colocalizes with apolipoprotein E. Arteriosclerosis Thromb Vasc Biol. 1997;17:2350-2358.
21. Grainger DJ, Metcalfe JC. Transforming growth factor-beta: the key to understanding lipoprotein (a)? Curr Opin Lipidol. 1995;6:81-85.
22. 22. Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation. 1997;95:1542-1548.
23. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
24. Cárcamo J, Weis FMB, Ventura F, Wieser R, Wrana JL, Attisano L, Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol. 1994;14:3810-3821.
25. Liu A, Ballermann BJ. TGF-β type II receptor in rat renal vascular development: localization to juxtaglomerular cells. Kidney Int. 1998;53: 716-725.
26. 3 in cardiomyocytes during pressure overloadinduced hypertrophy. J Mol Cell Cardiol. 1997;29:2213-2224.
27. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G. Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 1997;30:134-139.
28. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, Löpez LA. Langa C, Fabra A, Letarte M, Bernabéu C. Endoglin modulates cellular responses to TGF-β1. J Cell Biol. 1996;133:1109-1121.
29. Ward MR, Agrotis A, Jennings G, Bobik A. Vascular types I and II transforming growth factor-beta receptor expression: differential dependency on tyrosine kinases during induction by TGF-β. FEBS Lett. 1998;422:197-200.
30. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and proximity of platelet-derived growth factor and transforming growth factor-β. Am J Pathol. 1998;152: 533-546.